- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.04. | iSpecimen Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.03. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.03. | iSpecimen Inc. (ISPC) Q4 2023 Earnings Call Transcript | 2 | Insider Monkey | ||
| 14.03. | iSpecimen GAAP EPS of -$1.23, revenue of $1.7M | 2 | Seeking Alpha | ||
| 14.03. | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.03. | iSpecimen Inc: iSpecimen Reports Full Year 2023 Results | 117 | GlobeNewswire (Europe) | LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for... ► Artikel lesen | |
| 14.03. | iSpecimen Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 13.03. | iSpecimen: Q4 Earnings Insights | 2 | Benzinga.com | ||
| 13.03. | iSpecimen Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 13.03. | iSpecimen Inc: iSpecimen Reschedules Full Year 2023 Earnings Release and Conference Call | 2 | GlobeNewswire (USA) | ||
| 12.03. | Earnings Outlook For iSpecimen | 1 | Benzinga.com | ||
| 05.03. | iSpecimen Inc: iSpecimen to Report Full Year 2023 Financial Results on March 13, 2024 | 2 | GlobeNewswire (USA) | ||
| 05.03. | iSpecimen Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.02. | iSpecimen Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.01. | ISpecimen, TriMetis Life Sciences Announce Partnership For Tissue Research | 2 | RTTNews | ||
| 23.01. | iSpecimen enters into agreement with TriMetis Life Sciences | 1 | Seeking Alpha | ||
| 23.01. | iSpecimen Inc: iSpecimen and TriMetis Life Sciences Announce Strategic Partnership to Help Transform Tissue-Based Research | 621 | GlobeNewswire (Europe) | LEXINGTON, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical... ► Artikel lesen | |
| 18.01. | iSpecimen Inc: iSpecimen to Participate in Maxim Group Healthcare IT Virtual Conference, January 24 & 25, 2024 | 1 | GlobeNewswire (USA) | ||
| 21.12.23 | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.12.23 | iSpecimen Inc: iSpecimen Strengthens Global Oncology Biospecimen Offering | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,580 | -3,36 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| ILLUMINA | 110,06 | +0,40 % | Kurs fällt um 3,75 Prozent: Illumina-Aktie unter Druck (115,0253 €) | An der US-amerikanischen Börse fällt gegenwärtig die Illumina-Aktie negativ auf. Das Papier verliert deutlich an Wert. Mit einem Kurssturz von 3,75 Prozent gehört heute die Aktie von Illumina zu den... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 53,25 | -100,00 % | CRISPR Therapeutics' Options Frenzy: What You Need to Know | ||
| INTELLIA THERAPEUTICS | 19,530 | -2,54 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| EDITAS MEDICINE | 4,954 | -5,24 % | Editas Medicine, Inc.: Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates | Company aligned with FDA that RUBY is a single Phase 1/2/3 trial On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,010 | +6,99 % | Formycon, Defence Therapeutics, Morphosys - Mächtig Bewegung in der Biotechbranche | Aktuell richtet sich der Fokus der Anleger neben den wichtigsten Indizes wie DAX oder Dow Jones vor allem auf Gold oder Bitcoin, dagegen ist vom Biotechnologiesektor in den hiesigen Gazetten wenig zu... ► Artikel lesen | |
| BLUEBIRD BIO | 0,922 | +2,81 % | bluebird bio, Inc. - 8-K, Current Report | ||
| NEUROCRINE BIOSCIENCES | 122,55 | -1,57 % | Voyager Therapeutics, Inc.: Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment | LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 20,530 | -3,34 % | Arrowhead's plozasiran could reach $700M-plus in sales by 2032, meet major unmet need in dyslipidemia: GlobalData | ||
| GALAPAGOS NV | 27,000 | -0,74 % | Galapagos NV: Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 | Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / Richter transformation (RT)
Mechelen... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,867 | -6,20 % | Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products | IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON, April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 4,030 | -1,59 % | Cardiff Oncology, Inc.: Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study | RAS-mutated mCRC - In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization... ► Artikel lesen | |
| TWIST BIOSCIENCE | 26,880 | +0,90 % | Twist Bioscience Corporation: Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing | Precision Dx Products are CE-marked and compliant with EU IVDR 2017/746 regulations
Precision Dx Products include Twist Precision Prep and Enrichment Dx Kit, Twist Precision Exome Dx Panel and... ► Artikel lesen | |
| REPLIGEN | 146,60 | +3,24 % | Repligen Corporation: Repligen to Report First Quarter 2024 Financial Results | ||
| BEAM THERAPEUTICS | 23,930 | -1,56 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen |
ISPECIMEN INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -27,92 % bei einem Aktienkurs von 0,315 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
